Fourteen case studies (46 participants) were included.
Primary technical success was achieved in 44 (95.6%) of the 46 participants. Thirty-day clinical success was 93.4% (one participant developed thrombotic graft limb occlusion).
There were no procedure-related mortalities, and mortality at the end of study follow-ups was 13%. These deaths were reported in the studies to be unrelated to EVAR.
Maximum sac diameter decreased by a median of 11 mm (range: 0 to 60 mm) in 9 studies. Two studies reported that the sac shrank, but did not give details. Three studies reported that the aneurysm was excluded at the last follow-up.
Post-intervention PAF was reported in 43 participants: in 22 (51.2%) PAF regressed, in 18 (41.8%) it remained unchanged, and in 3 (7%) it progressed.
In the 11 studies that reported on renal impairment, 24 (58.5%) participants showed signs of renal impairment. Of these participants, 11 (45.8%) showed no renal impairment after treatment and 13 (54.2%) had no change in symptoms.
In terms of graft-related complications, 4 (9%) of those successfully treated had endoleaks: 3 with type III endoleaks and one with type II endoleak. Three other participants developed graft-related complications during the follow-up periods. Fourteen re-interventions in total had to be performed on 8 participants during follow-up.